Expert Q&A on Patent Eligibility of Life Sciences Inventions

Some experts have called the standards for determining patent eligibility under Section 101 of the Patent Act incoherent. This “incoherence” is particularly challenging for the life sciences industry where certain diagnostic inventions are now unpatentable. In this Q&A, Finnegan attorneys Charles Collins-Chase and Sara Leiman address patent subject matter eligibility, global patent strategies for protecting life sciences inventions, and other legal and regulatory mechanisms to protect life sciences inventions.